Antibody responses to SARS‐CoV‐2 in healthy individuals returning to Shenzhen

Abstract

To verify reliability of antibody detection and investigate population immunity to severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) in the local Chinese population. A cross-sectional study was conducted in Shenzhen to detect anti-coronavirus antibodies including, immunoglobulin G (IgG), immunoglobulin M (IgM), and immunoglobulin A (IgA). In the COVID-19 group, nine patients were enrolled after diagnosis. In the control group, 1589 individuals without clinical symptoms (cough, fever, and fatigue) and returning from outside Shenzhen were enrolled. The first study enrollment occurred at the end of February 2020; the final study visit was 18 March 2020. In the COVID-19 group, the seven of nine patients were positive for IgM, IgG, and IgA. Meanwhile, six of the 1589 healthy individuals were found to be weakly positive for IgG. According to SARS-CoV-2 nucleic acid tests, the six individuals were all negative. Strong supplemental support for clinical information can be provided by antibody detection, especially for IgA. According to comparison with overseas reports, the infection rate of the Chinese population outside Shenzhen, China, is significantly low, so most of the population in China is still susceptible. Hence, social distancing measures are still inevitable until a vaccine is developed successfully.

Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children

“…Considering the pivotal role of the IgA on mucosal immunity, while clinicians are mainly focused on IgM and IgG, we chose to evaluate the IgA instead of IgM ratios. Consistently, it was speculated in a study by Zhang et al [ 47 ] that IgA-based ELISA kit is a more sensitive tool than IgM and IgG, for diagnosing acute COVID-19. Besides, we aimed to perform the long-term monitorization of antibody levels in seropositive subjects in future studies.…”